Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Inclusion Criteria:

Histologically documented metastatic renal cell cancer with a component of clear cell histology.
Evidence of measurable disease.
Patients with mRCC must have received no prior systemic first-line therapy or must have progressive disease per RECIST (version 1.0) after one prior systemic first line regimen for metastatic disease containing sunitinib, cytokine(s), or both.

Exclusion Criteria:

Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy.
Major surgery less that 4 weeks or radiation less than 2 weeks of starting study drug.